Please login to the form below

Not currently logged in
Email:
Password:

nusinersen

This page shows the latest nusinersen news and features for those working in and with pharma, biotech and healthcare.

Biogen reports new data backing long-term benefit of Spinraza

Biogen reports new data backing long-term benefit of Spinraza

This includes new analysis of data from Biogen’s NURTURE study, which showed 92% of patients who started Spinraza (nusinersen) treatment as pre-symptomatic infants maintained the ability to swallow after

Latest news

More from news
Approximately 4 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    95.  Ionis (US). Biogen (US). Exercise option .  Nusinersen, in phase III for treatment for spinal muscular atrophy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Article: Market access in Brazil

    In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...